IP Library › Granted Patent US 10,946,086
Granted Patent B2
US 10,946,086 · App. 16/245,378 · Granted Mar 16, 2021

Group B

Inventors: Annaliesa Sybil Anderson (Upper Saddle River, NJ); Amardeep Singh Bhupender Bhalla (Montvale, NJ); Robert G. K. Donald (South Orange, NJ); Jianxin Gu (Paramus, NJ); Kathrin Ute Jansen (New York, NY); Rajesh Kumar Kainthan (Tappan, NY); Lakshmi Khandke (Nanuet, NY); Jin-Hwan Kim (Suffern, NY); Paul Liberator (Holmdel, NJ); Avvari Krishna Prasad (Chapel Hill, NC); Mark Edward Ruppen (Garnerville, NY); Ingrid Lea Scully (Cornwall, NY); Suddham Singh (Monroe, NY); Cindy Xudong Yang (Tappan, NY)
Assignee: Pfizer Inc.
A61K39/092A61K39/39A61K39/40A61K47/10A61K47/26C07K16/1275C07K16/44A61K2039/505A61K2039/55A61K2039/55505A61K2039/55566A61K2039/55577A61K2039/6037A61K2039/70Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,946,086
App. No.
16/245,378
Granted
Mar 16, 2021
Kind
B2
Abstract

The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae , commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Claims (7)

1. A method of inducing an immune response against group B streptococcus (GBS) comprising administering to a subject an effective amount of an immunogenic composition comprising polysaccharide-protein conjugates, wherein the conjugates comprise capsular polysaccharides from GBS serotypes Ia, Ib, II, III, IV and V, and wherein at least one of the capsular polysaccharides has a sialic acid level of greater than about 60%.

2. The method according to claim 1 , wherein the subject is a female.

3. The method according to claim 2 , wherein the female is pregnant.

4. The method according to claim 3 , wherein the pregnant female is at least at 20 weeks gestation.

5. The method according to claim 1 , wherein the subject is immunocompromised.

6. The method according to claim 1 , wherein the subject has a medical condition selected from the group consisting of obesity, diabetes, HIV infection, cancer, cardiovascular disease, and liver disease.

7. The method according to claim 1 , wherein the group B streptococcus is Streptococcus agalactiae.

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →
Cited By (1)
US 12,527,855